Rapport Therapeutics, Inc.

Today, RAPP trades at 24.98 USD.

For broader market analysis, dive into the technicals on the Rapport Therapeutics, Inc. stock price chart and read the latest RAPP news:
– Rapport Therapeutics, Inc. Stock 12‑Month Price Target Cut to $65.43, Implies 157% Upside
– Rapport Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
– Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

Markets don't sleep, here's what's going on with RAPP at the moment:
– Rapport Therapeutics, Inc. Stock 12‑Month Price Target Cut to $65.43, Implies 157% Upside
– Rapport Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
– Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

See more updates in real-time with our News Flow.

Rapport Therapeutics, Inc. is scheduled to release its next earnings report on Mar 16, 2027.

Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release

How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts

RAPP stock is 4.81% volatile and has beta coefficient of 1.99.

What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable

Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like RAPP are typically less volatile than smaller companies

Track every detail on Rapport Therapeutics, Inc. stock chart and check out the list of the most volatile stocks — is Rapport Therapeutics, Inc. there?

To understand the RAPP stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — +1.93%
– 1 week — +14.99%
– 1 month — −19.52%

RAPP all-time low was 6.43 USD (Mar 4, 2025), and its highest price is 52.93 USD (Aug 27, 2026). Find more dynamics in the Stock Heatmap and on the Rapport Therapeutics, Inc. stock chart.

Rapport Therapeutics, Inc. market capitalization is ‪1.24 B‬, representing the total value of all its outstanding shares (price × shares outstanding).

What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements

What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Rapport Therapeutics, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Rapport Therapeutics, Inc. stacks up against other companies

The safest way to buy Rapport Therapeutics, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.

You can trade RAPP directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart

Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.

As of Nov 5, 2026, the company has 84 employees.

Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements

See our rating of the largest employers to find more opportunities.

Rapport Therapeutics, Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Rapport Therapeutics, Inc. stocks trade under the symbol RAPP.

About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners

Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion

Learn how to find your desired assets in our Symbol Search.

RAPP earnings for the last quarter are −0.84 USD per share, whereas the estimation was −1.20 USD, resulting in a 30.21% surprise. The estimated earnings for the next quarter are −0.95 USD per share.

How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one

Follow other essential metrics in Rapport Therapeutics, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk

Rapport Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD despite the estimated figure of 0.00 USD. In the next quarter revenue is expected to reach ‪7.14 K‬ USD.

How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance

Follow other essential metrics in Rapport Therapeutics, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses

Yes, you can track Rapport Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.

Use our Earnings Calendar to never miss important releases and spot opportunities early.

RAPP net income for the last quarter is ‪−40.23 M‬ USD, while the quarter before that showed ‪−56.62 M‬ USD of net income which accounts for 28.93% change.

How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result

Follow other essential metrics in Rapport Therapeutics, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control

No, Rapport Therapeutics, Inc. does not currently pay dividends to its shareholders.

Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.

What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends

RAPP reached its all-time high of 52.93 USD on Aug 27, 2026. Its all-time low was 6.43 USD and was reached on Mar 4, 2025.

Explore the Rapport Therapeutics, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.